[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338781-105":59,"doc-detail-338781-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","improving-susceptibility-of-neuroendocrine-tumors-to-radionuclide-therapies-personalized-approaches-towards-complementary-treatments","Improving susceptibility of neuroendocrine tumors to radionuclide therapies - personalized approaches towards complementary treatments","","Radionuclide therapies support management of neuroendocrine neoplasms (NENs), with routine use of [131I]MIBG and [177Lu]Lu-DOTA-TATE for selected subtypes such as pheochromocytomas, paragangliomas, and gastroenteropancreatic tumors. Evidence also shows responses in some other NEN forms, but no unified guidance exists and complete remissions are rare. This review summarizes current radionuclide approaches and advances in theranostic agents, discussing radioresistance mechanisms linked to cancer cell stemness and the role of molecular inhibition, alongside approved targeted therapies for combination in personalized molecular profiling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/improving-susceptibility-of-neuroendocrine-tumors-to-radionuclide-therapies-personalized-approaches-towards-complementary-treatments/338781/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/improving-susceptibility-of-neuroendocrine-tumors-to-radionuclide-therapies-personalized-approaches-towards-complementary-treatments/338781.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which radionuclide therapies are routinely used for neuroendocrine neoplasm patients?","Question",{"text":112,"@type":113},"The review highlights routine use of [131I]MIBG and [177Lu]Lu-DOTA-TATE for treating a subset of NENs, including pheochromocytomas, paragangliomas, and gastroenteropancreatic tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are better combination treatment strategies needed?",{"text":117,"@type":113},"Although these therapies can delay disease progression and improve quality of life, complete remissions are achieved rarely, so more individually tailored combination regimens are required.",{"name":119,"@type":110,"acceptedAnswer":120},"What biological mechanisms are discussed as contributors to radioresistance?",{"text":121,"@type":113},"The review discusses molecular pathways involved in NEN tumorigenesis and progression that mediate radioresistance, particularly pathways related to the stemness of cancer cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338781,1790112532,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Review  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2024; 14(1): 17-32. doi: 10.7150/thno.87345  \nImproving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments  \nSusan Richter1􀀍, Charlotte Steenblock2, Alessa Fischer3, Sandy Lemm4,7, Christian G. Ziegler2,5, Nicole Bechmann1, Svenja Nölting3,6, Jens Pietzsch4,7*, Martin Ullrich4*􀀍  \n1. Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.  \n2. Department of Internal Medicine III, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.  \n3. Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.  \n4. Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.  \n5. University Hospital Würzburg, Division of Endocrinology and Diabetes, Würzburg, Germany.  \n6. Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.  \n7. Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany.  \n* Shared senior authorship.  \n􀀍 Corresponding authors: [Dr. Martin Ullrich: m.ullrich@hzdr.de](Dr. Martin Ullrich: m.ullrich@hzdr.de); Dr. Susan Richter: [Susan.Richter@ukdd.de](Susan.Richter@ukdd.de).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2023.06.20; Accepted: 2023.09.30; Published: 2024.01.01  \nAbstract  \nRadionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [131I]MIBG and [177Lu]Lu-DOTA-TATE are routinely used for the treatment of a subset of NENs, including pheochromocytomas, paragangliomas and gastroenteropancreatic tumors. Some patients suffering from other forms of NENs, such as medullary thyroid carcinoma or neuroblastoma, were shown to respond to radionuclide therapy; however, no general recommendations exist. Although [131I]MIBG and [177Lu]Lu-DOTA-TATE can delay disease progression and improve quality of life, complete remissions are achieved rarely. Hence, better individually tailored combination regimes are required. This review summarizes currently applied radionuclide therapies in the context of NENs and informs about recent advances in the development of theranostic agents that might enable targeting subgroups of NENs that previously did not respond to [131I]MIBG or [177Lu]Lu-DOTA-TATE. Moreover, molecular pathways involved in NEN tumorigenesis and progression that mediate features of radioresistance and are particularly related to the stemness of cancer cells are discussed. Pharmacological inhibition of such pathways might result in radiosensitization or general complementary antitumor effects in patients with certain genetic, transcriptomic, or metabolic characteristics. Finally, we provide an overview of approved targeted agents that might be beneficial in combination with radionuclide therapies in the context of a personalized molecular profiling approach.  \nIntroduction  \nNeuroendocrine neoplasms (NENs) are a heterogeneous group of tumors affecting neuroendocrine cells and arise in many different organs. NENscan occur in the digestive tract from enterochromaffin cells, the pancreas from islet or ductal cells, the lungs from pulmonary neuroendocrine cells, and the  \nthyroid from parafollicular C-cells. Furthermore, pheochromocytomas originate from chromaffin cells of the adrenal medulla and paragangliomas from extra-","cbCaij3COiUIiE74","https://ap.wps.com/l/cbCaij3COiUIiE74","pdf",2757841,16,"English","# Abstract\n# Introduction\n## Neuroendocrine neoplasms overview\n## Gastroenteropancreatic NEN grading and clinical features\n## Medullary thyroid carcinoma and treatment approaches\n## PPGL (pheochromocytoma/paraganglioma) symptoms and clinical context","[{\"question\":\"Which radionuclide therapies are routinely used for neuroendocrine neoplasm patients?\",\"answer\":\"The review highlights routine use of [131I]MIBG and [177Lu]Lu-DOTA-TATE for treating a subset of NENs, including pheochromocytomas, paragangliomas, and gastroenteropancreatic tumors.\"},{\"question\":\"Why are better combination treatment strategies needed?\",\"answer\":\"Although these therapies can delay disease progression and improve quality of life, complete remissions are achieved rarely, so more individually tailored combination regimens are required.\"},{\"question\":\"What biological mechanisms are discussed as contributors to radioresistance?\",\"answer\":\"The review discusses molecular pathways involved in NEN tumorigenesis and progression that mediate radioresistance, particularly pathways related to the stemness of cancer cells.\"}]","Improving susceptibility of neuroendocrine tumors to radionuclide therapies - personalized approaches towards complementary treatments | PDF",1790025614,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a99f50b4c62773175a05914b89dfcd7b.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5671fd190194414a5ecf5c8441b1d4ed.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f9085b0c447aa30180dbe9713d53478.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9a7ce42b3cb14a35646a2d65e29c017.webp",980,1268]